Wellington Management Group LLP Has $218.59 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Wellington Management Group LLP grew its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 7.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,618,359 shares of the company's stock after purchasing an additional 308,954 shares during the period. Wellington Management Group LLP owned approximately 7.13% of Kymera Therapeutics worth $218,587,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Quarry LP bought a new position in Kymera Therapeutics in the 3rd quarter worth about $95,000. HighTower Advisors LLC bought a new position in Kymera Therapeutics in the 3rd quarter worth about $494,000. HighVista Strategies LLC bought a new position in Kymera Therapeutics in the 3rd quarter worth about $603,000. Cinctive Capital Management LP bought a new position in Kymera Therapeutics in the 3rd quarter worth about $2,688,000. Finally, Bamco Inc. NY bought a new position in Kymera Therapeutics in the 3rd quarter worth about $1,183,000.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 15.82% of the company's stock.

Analyst Upgrades and Downgrades

KYMR has been the subject of several recent analyst reports. Wolfe Research upgraded shares of Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 target price for the company in a research report on Monday, August 26th. BMO Capital Markets started coverage on shares of Kymera Therapeutics in a research note on Friday. They issued a "market perform" rating and a $55.00 price target for the company. Leerink Partnrs raised shares of Kymera Therapeutics to a "strong-buy" rating in a research note on Monday, September 9th. Morgan Stanley upped their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 6th. Finally, Oppenheimer upped their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Friday, September 27th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Kymera Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $53.50.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR traded down $3.02 during mid-day trading on Monday, hitting $43.65. The stock had a trading volume of 663,028 shares, compared to its average volume of 582,138. The company has a market cap of $2.83 billion, a PE ratio of -18.53 and a beta of 2.16. Kymera Therapeutics, Inc. has a 12-month low of $21.20 and a 12-month high of $53.27. The company's 50 day moving average is $46.40 and its 200-day moving average is $42.64.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm's quarterly revenue was down 20.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.90) EPS. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.